ProfileGDS4814 / ILMN_2367172
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 79% 80% 78% 79% 81% 80% 81% 81% 80% 82% 81% 80% 80% 79% 80% 79% 80% 80% 79% 80% 79% 81% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)129.66379
GSM780708Untreated after 4 days (C2_1)150.38180
GSM780709Untreated after 4 days (C3_1)125.34878
GSM780719Untreated after 4 days (C1_2)135.31479
GSM780720Untreated after 4 days (C2_2)152.19981
GSM780721Untreated after 4 days (C3_2)142.23680
GSM780710Trastuzumab treated after 4 days (T1_1)152.01381
GSM780711Trastuzumab treated after 4 days (T2_1)153.58981
GSM780712Trastuzumab treated after 4 days (T3_1)140.09380
GSM780722Trastuzumab treated after 4 days (T1_2)178.83582
GSM780723Trastuzumab treated after 4 days (T2_2)152.8981
GSM780724Trastuzumab treated after 4 days (T3_2)142.21680
GSM780713Pertuzumab treated after 4 days (P1_1)146.28180
GSM780714Pertuzumab treated after 4 days (P2_1)138.16379
GSM780715Pertuzumab treated after 4 days (P3_1)139.63180
GSM780725Pertuzumab treated after 4 days (P1_2)131.48479
GSM780726Pertuzumab treated after 4 days (P2_2)143.84980
GSM780727Pertuzumab treated after 4 days (P3_2)143.11780
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)138.12979
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)150.21780
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)134.36179
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)162.63481
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)156.91181